Palvella Therapeutics (PVLA) Stock: Buy, Sell, or Hold?
PVLA - Palvella Therapeutics, Inc. Common Stock
$150.13
-0.26 (-0.17%)
▼
5d:
-3.43%
30d:
-3.19%
90d:
+41.13%
HOLD
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When PVLA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PVLA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: PVLA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: PVLA is currently trading at $150.13, which is considered fair relative to its 30-day fair value range of $148.08 to $155.77.
Technical Outlook: Technically, PVLA is in a strong uptrend. Immediate support is located at $143.47, while resistance sits at $157.93.
Market Sentiment: PVLA scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $230.53 (+53.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PVLA is in a strong uptrend. Immediate support is located at $143.47, while resistance sits at $157.93.
Market Sentiment: PVLA scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $230.53 (+53.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$148.08 -
$155.77
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (37/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 53.6% below Wall St target ($230.53)
Trading Range Analysis
30-Day Trading Range
$148.08 -
$155.77
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$11.74
(7.8%)
Support & Resistance Levels
Support Level
$143.47
Resistance Level
$157.93
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-20.02
Wall Street Target
$230.53
(+53.6%)
Share & Embed Analysis
Last updated: September 12, 2026 10:15 AM ET
Data refreshes hourly during market hours. Next update: 11:15 AM
Data refreshes hourly during market hours. Next update: 11:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PVLA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Kathleen Goin
SELL
4302 shares
2026-03-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
